Stock sales
Three US senators cite research by Professor Alan Jagolinzer of Cambridge Judge Business School in urging SEC reform of insider trading laws. Professor Alan Jagolinzer Three US senators cited research co-authored by Professor Alan Jagolinzer of Cambridge Judge Business School in urging the Securities…
Good reporting
Annual reports should inform society – not just shareholders – about vital issues such as the financial health and environmental impact of organisations, says Professor Alan Jagolinzer of Cambridge Judge Business School. Professor Alan Jagolinzer By Professor Alan Jagolinzer Corporate…
Forbes India: How drug companies can increase their R&D effectiveness
A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…
Call for SEC action
Article co-authored by Professor Alan Jagolinzer of Cambridge Judge calls for Securities and Exchange Commission to reform 'pre-planned' stock sale rules. Professor Alan Jagolinzer An article co-authored by Professor Alan Jagolinzer of Cambridge Judge Business School in The Hill, a…
Cambridge Network: Study examines cultural fit in big pharma integration
Piyush Durani, an Executive MBA graduate of Cambridge Judge (EMBA 2018), measures cultural fit in the $74 billion merger of Bristol-Myers Squibb and Celgene. “As I progressed through my EMBA programme in 2018-2019, the BMS acquisition of Celgene was announced…
Big pharma
Piyush Durani, an Executive MBA graduate of Cambridge Judge (EMBA 2018), measures cultural fit in the $74 billion merger of Bristol-Myers Squibb and Celgene. Piyush Durani The well-known business expression "culture eats strategy for breakfast" is particularly apt for mergers…
Pharma shift
The pharmaceutical industry's focus on procedures and dealmaking could change significantly in this uncertain period, five Cambridge Executive MBA graduates say in a webinar for the What's Next? How to Survive and Thrive in a Post COVID-19 World series. Here's…
Investing in Cambridge drug discovery
PharmEnable raises £1.8 million for drug discovery expansion. PharmEnable, a venture supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School, said it has secured £1.8 million in a seed financing round led by Cambridge…
Biotech vs big pharma
Most approved "priority" medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study at the University of Cambridge Judge Business School. Biotech companies created 40 per cent more US Food & Drug Administration-approved "priority" drugs than…
Manhattan Project?
A "multiple-shots-on-goal" approach is needed to find coronavirus drugs, Cambridge Judge academics say in California Management Review. A many-shots-on-goal approach - not command and control - will most effectively develop vaccines and treatments for COVID-19 (coronavirus), Cambridge Judge Business School academics say in a new California Management Review article. Professor Christoph Loch While some have suggested…
